Japan OKs MediciNova Patent for Ibudilast Plus Riluzole in Treating ALS

Japan OKs MediciNova Patent for Ibudilast Plus Riluzole in Treating ALS

284324

Japan OKs MediciNova Patent for Ibudilast Plus Riluzole in Treating ALS

A patent application allowing MediciNova to use its investigational therapy ibudilast (MN-166) in combination with riluzole to treat people with amyotrophic lateral sclerosis (ALS) has been approved for issue in Japan. The patent request filed with the Japan Patent Office covers a wide range of oral doses and dosing regiments for both ibudilast and riluzole, and grants MediciNova exclusive rights over this combination in treating ALS, including alleviating symptoms and slowing disease progression, should ibudilast be approved for this patient…

You must be logged in to read/download the full post.